[Introduction]Switching to generic drugs during paclitaxel/carboplatin (TC) therapy increased the incidence of extravasation, while switching back to brand-name drugs decreased the incidence of adverse events in gynecologic patients receiving outpatient chemotherapy. [Methods]The medical records of gynecologic patients who had received outpatient TC therapy between January 2013 and December 2016 (initial brand-name drug period:n=238, generic drug period:n=141, subsequent brand-name drug period:n=158) were retrospectively examined. [Results]The incidence of extravasation increased significantly during the generic drug period (initial brand-name drug period:1.3%, generic drug period:
9.3%, subsequent brand-name drug period:1.6%;P<0.01). A multivariate analysis adjusted for age, number of TC therapy sessions, body mass index (BMI), and use of generic drugs showed that the odds ratio for vascular complications associated with generic drugs was 6.8 (95% confidence interval [CI]:4.1-11.3). [Conclusion]The use of generic drugs in TC therapy increases the incidence of vascular complications, such as extravasation and phlebitis.
View full abstract